ARA-290

ARA-290 is a small piece of erythropoietin (EPO), the hormone that tells the body to make red blood cells. It was engineered to keep EPO's tissue-repair job and discard its blood-making job, so it calms inflammation and switches on repair at damaged tissue without raising red cell count, hemoglobin, or clotting risk. That separation is the whole point of the molecule, and every human trial that checked confirmed it: hemoglobin did not move¹ ⁴ ⁵.

The strongest human data is narrow but real. In Phase 2 trials in sarcoidosis-associated small fiber neuropathy, and one trial in painful diabetic neuropathy, ARA-290 increased objective markers of small-nerve regeneration and improved neuropathic symptom scores⁴ ⁵ ⁶ ⁷. It is one of the few compounds with human evidence of nerve-fiber regeneration markers, rather than only symptom suppression like gabapentin or duloxetine. The honest caveat sits right next to that: the trials are small, pain endpoints were muddied by large placebo effects, and an eye trial (diabetic macular edema) missed its primary endpoint⁸.

ARA-290 was never approved. It holds FDA Fast Track and Orphan Drug designation for sarcoidosis, but no Phase 3 trial was ever started and the developer has been dormant since 2020. So this is a compound with unusually clean early science that stalled commercially, not one that failed. Where it is most plausible: neuropathic pain with active nerve injury or inflammation. Where it is a poor fit: healthy tissue, and mechanical or joint pain.

What ARA-290 is

ARA-290 (also called cibinetide) is an 11-amino-acid peptide copied from one surface of erythropoietin¹. When researchers mapped EPO's three-dimensional shape, they found that one face, called helix B, points away from the receptor that makes red blood cells and instead contacts a different receptor that drives tissue repair. ARA-290 reproduces that surface in a short peptide that activates the repair receptor while not touching the blood-making one¹.

The result is a molecule that delivers EPO's protective effect without its liabilities: no blood thickening, no thrombosis risk, no need for hemoglobin monitoring. That is not a marketing line; it is the reason the molecule was built, and it is confirmed in the human safety data¹ ⁴ ⁵.

How ARA-290 works

It acts only where there is damage

ARA-290 works through the innate repair receptor (a two-part complex of the EPO receptor and a partner called CD131). The key fact is that this receptor is largely absent in healthy tissue and appears in response to injury, inflammation, or metabolic stress¹. So the drug has something to act on only where tissue is already hurt. This single fact explains most of what follows, including why it is a poor fit for healthy people.

When it binds that receptor, it sets off signaling that calms inflammation and supports cell survival and repair (JAK2/STAT and PI3K/Akt signaling, with reduced activity of the inflammation switch NF-κB)¹ ². It is not a painkiller in the usual sense. It works on the underlying nerve damage rather than masking the pain signal.

The receptor dependence is well proven

The clearest evidence that this is the real mechanism comes from removing the receptor. In a rat nerve-injury study, ARA-290 relieved touch and cold hypersensitivity, and the effect disappeared completely in mice bred without the CD131 partner³. The same receptor dependence was later shown in a stroke model (silencing CD131 abolished the protection) and in a colitis model (no effect in CD131-knockout cells)⁹ ¹⁰. Three independent studies, three organ systems, same answer.

Why it does not make red blood cells

EPO's blood-making effect requires a different receptor arrangement (an EPO-receptor pair in bone marrow) that ARA-290 does not engage. In the knockout studies above, removing CD131 abolished ARA-290's tissue protection while red cell production carried on normally³ ⁹. In human trials, hemoglobin, hematocrit, and platelet counts did not change, and no anti-drug antibodies were detected⁴ ⁵.

The short-half-life paradox

ARA-290 leaves the bloodstream fast: about 2 minutes after an IV dose and about 20 minutes after a subcutaneous one². Peak blood level after 4 mg subcutaneous is around 2 ng/mL in the dedicated pharmacokinetic study, just above the level needed to activate the receptor². Yet the effects last days to months. The receptor appears to act like a switch: the drug flips it on and clears, and the cell keeps running the repair program. In the sarcoidosis trial, benefit was still measurable nine months after the last dose⁶. This is why the drug is dosed daily rather than continuously, and why a short course can produce lasting effect.

What the human trials found

Four small human trials carry the clinical evidence. The objective nerve-regeneration measurements were the clearest wins; the subjective pain scores were less clean because placebo groups also improved.

Sarcoidosis nerve pain: the best-supported use

Three trials tested ARA-290 in sarcoidosis with painful small fiber neuropathy, where small sensory nerves die back and cause burning, numbness, and touch sensitivity. The dose-ranging DOSARA trial is the most informative. At 4 mg daily for 28 days, the primary measure (corneal nerve fiber area, by confocal microscopy) increased significantly versus placebo, while 1 mg and 8 mg did not, which is where the dose sweet spot comes from⁵.

The often-quoted "23% increase" is in GAP-43-positive regenerating fibers from skin biopsy, measured at the 4 mg dose, not in corneal nerve fiber area⁵. GAP-43 marks actively regrowing nerve fibers, so this is a regeneration signal rather than only survival. Two things should be said plainly alongside it: standard intraepidermal nerve fiber density (a count of existing fibers) did not change in that trial, and between-group pain did not reach statistical significance (p=0.157)⁵. The structural-regeneration and symptom-score signals were real; the pain-score signal was not clean.

The earlier IV pilot found a symptom-score improvement of 11.5 points versus 2.9 for placebo, with 42% of treated patients reaching a clinically meaningful 15-point improvement versus none on placebo, and no change in hemoglobin⁴.

Painful diabetic neuropathy

One trial tested 4 mg daily for 28 days in type 2 diabetics with painful neuropathy. It improved neuropathic symptom scores (p=0.037) and produced a small drop in long-term blood sugar (HbA1c down 0.21%, p=0.002). Nerve fiber density improved only in the subgroup that started with documented nerve-fiber loss⁷.

Diabetic macular edema: a miss worth stating

A 12-week open-label pilot in 9 patients with diabetic macular edema failed its primary vision endpoint⁸. A few patients showed exploratory signals (some with abnormal baseline kidney protein values improved), but the trial was small, uncontrolled, and negative on its main goal. The authors flagged that a fixed 4 mg dose may be too low in people with very high body weight, which is worth keeping in mind for dosing.

The preclinical breadth

Beyond nerves, animal and cell studies show a broad tissue-protective pattern: kidney protection after loss-and-restoration of blood flow¹¹, reduced cardiac inflammation and preserved heart function in aged rats¹², gut-inflammation control in colitis¹⁰, brain protection in stroke models⁹, and wound, bone, and transplanted-islet protection. These are consistent with the mechanism and broaden the picture, but they are mostly rodents and cell dishes, not people.

Who ARA-290 may help, and who it will not

The deciding question is whether the pain is genuinely from a nerve. ARA-290 acts on small-nerve injury and inflammation. It does nothing for muscle, tendon, or joint pain.

A good fit looks like: burning, tingling, electric, or shooting pain; skin that is hypersensitive to light touch (allodynia); symptoms that follow a nerve territory; numbness or temperature and sweating changes. These point to small-fiber nerve involvement, which is the right target.

A poor fit looks like: deep ache, soreness, or stiffness that tracks with load and rest; swelling, warmth, and redness (that is inflammatory or mechanical, not neuropathic); pure weakness without sensory symptoms; or imaging that shows ongoing structural damage. In those cases a structural-repair approach such as BPC-157 and TB-500 is the better starting point.

A note on off-label use, including post-surgical nerve pain

This distinction matters for common questions like lingering nerve pain after a surgery such as ACL reconstruction, where the saphenous nerve and its branches are often irritated and leave tingling or touch-sensitive skin around the knee. Two things need to be kept separate:

• The reason to think it would help here is preclinical. The closest evidence is a rat study of a surgical nerve injury, where ARA-290 relieved touch and cold hypersensitivity and the effect vanished without the receptor³. That is a strong mechanistic match, but it is an animal model. No human trial has tested post-surgical nerve pain.
• What the human trials add is mainly a safety signal, within limits, plus proof the mechanism works in human nerves. Humans tolerated it well in the sarcoidosis and diabetic trials, and those trials showed the nerve-repair effect is real in people, just in different conditions. The leap to a post-surgical setting is a context leap, not a from-scratch one, and it remains untested.

Put simply: for any use outside sarcoidosis and diabetic neuropathy, the case for whether it works is preclinical, and the case for whether it is tolerable is a limited human safety signal. Natural healing also improves most post-surgical nerve irritation over many months, which makes any individual result hard to attribute.

The 4 mg dose is the trial-anchored choice, and the dose-ranging data is unusually clear that higher is not better: 8 mg added nothing over 4 mg, and 1 mg was below the useful range⁵. There is no reason to escalate past 4 mg.

An intravenous alternative (2 mg three times weekly for 4 weeks) produced comparable outcomes in the early sarcoidosis work, but it requires a clinical setting and offers no advantage for most people⁴.

Reconstitution: use bacteriostatic water; isotonic (sodium-chloride-containing) diluent reduces injection sting. Use the reconstitution calculator for exact volumes, and inject ARA-290 in its own syringe rather than mixing with other peptides.

A practical reality check: there is no approved product. Access depends on research-peptide suppliers of variable quality, so purity and identity are not guaranteed.

What to expect over a course

Reported patterns from the trials, not guarantees:

• Weeks 1 to 2: some people notice burning and tingling starting to settle.
• Weeks 2 to 4: most of the measured symptom change in the trials had occurred by the end of the 4-week course.
• After stopping: benefit persisted for months in the sarcoidosis trial. Symptom scores held at 12 weeks after the last dose, and nerve-fiber measures kept improving after dosing stopped⁶. This is consistent with the switch-like mechanism.

Signs it may be helping: burning and touch sensitivity fading, less guarded movement, and better tolerance of physical therapy without nerve flares. If pain is mechanical or structural, expect little from it, which is itself useful information about what kind of pain you are dealing with.

ARA-290 is used as a defined course (4 to 12 weeks), not as ongoing therapy. A repeat course is reasonable if symptoms return after several months. There is no multi-year human data to support indefinite use.

Side effects and safety

Across the Phase 2 trials, ARA-290 was well tolerated, with side-effect rates similar to placebo⁴ ⁵ ⁷.

Common: mild injection-site reactions, transient headache, fatigue.

The core safety advantage: no clinically significant change in hemoglobin, hematocrit, or platelets, and no anti-drug antibodies⁴ ⁵. This is the practical payoff of the non-erythropoietic design, and it is why the mechanism is interesting for people in whom EPO would be risky.

Where the safety signal has limits, stated plainly:

• Total human exposure is small (dozens of patients per trial) and short (12 weeks is the longest controlled course, in 8 people)⁸.
• It is not spotless. The diabetic neuropathy trial had one possibly-related worsening of kidney function and one fatal heart attack judged unrelated to the drug; the 8 mg arm of the dose-ranging trial had one case of suicidal ideation⁵ ⁷. These were in patients with serious underlying disease, but they belong in an honest accounting.
• There is no chronic-use or multi-year safety data.

So the right phrasing is a reassuring safety signal, not established long-term safety.

Development status

ARA-290 reached the end of Phase 2 and then stopped. It earned US and EU Orphan Drug designation and US FDA Fast Track designation for sarcoidosis-associated small fiber neuropathy, and completed an end-of-Phase-2 FDA meeting. No Phase 3 trial was ever registered, and the developer (Araim Pharmaceuticals) has shown no public activity since 2020. The most likely explanation is a funding gap rather than a scientific failure, since Phase 3 programs typically require far more capital than a small orphan-drug developer can raise.

Academic work on the mechanism continues. Recent studies report reduced cardiac inflammation in aged rats¹² and brain protection through the CD131 receptor in stroke models⁹, but these are preclinical and not part of an active drug program.

FAQ

Related topics

• BPC-157 Guide — core repair peptide for vascular access and tissue healing
• TB-500 Guide — Thymosin Beta-4 for cellular mobility and repair
• SS-31 Guide — mitochondrial-support peptide for energy-limited repair
• NAD+ Guide — cellular energy support during nerve repair
• Tesamorelin Guide — GH-axis support often layered after nerve pain resolves
• Reconstitution Guide — step-by-step peptide mixing
• Injury Recovery Protocol — where ARA-290 fits for neuropathic injuries

References

¹ Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin — helix B surface peptide design, EPO-receptor/CD131 mechanism, non-erythropoietic profile. Proc Natl Acad Sci USA 2008;105:10925–10930. PMID 18676614

² Niesters M, Swartjes M, Heij L, et al. The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain — pharmacokinetics (Cmax, half-life), minimum effective concentration, switch-like pharmacodynamics. Expert Opin Orphan Drugs 2013;1(1):77–87. DOI 10.1517/21678707.2013.719289

³ Swartjes M, Morariu A, Niesters M, et al. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain — rat spared-nerve-injury model, β-common-receptor (CD131) knockout abolishes effect. Anesthesiology 2011;115:1084–1092. PMID 21873879 · DOI 10.1097/ALN.0b013e31822fcefd

⁴ Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — 2 mg IV, SFNSL improvement, hemoglobin unchanged. Mol Med 2012;18:1430–1436. PMID 23168581

⁵ Culver DA, Dahan A, Bajorunas D, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain (DOSARA, n=64) — primary endpoint corneal nerve fiber area; GAP-43-positive fiber length +23% from baseline at 4 mg (p=0.035); IENFD null; pain not significant (p=0.157). Invest Ophthalmol Vis Sci 2017;58:BIO52–BIO60. PMID 28475703

⁶ Dahan A, Dunne A, Swartjes M, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — 4 mg SC, CNFA +14.5% (p=0.022), 9-month sustained benefit. Mol Med 2013;19:334–345. PMID 24136731

⁷ Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — HbA1c −0.21% (p=0.002), PainDetect improvement (p=0.037), CNFD subgroup. Mol Med 2015;20:658–666. PMID 25387363

⁸ Lois N, Gardner E, McFarland M, et al. A phase 2 clinical trial on the use of cibinetide for the treatment of diabetic macular edema — open-label, n=9, primary visual acuity endpoint not met; fixed-dose/body-weight caveat. J Clin Med 2020;9:2225. PMID 32674280

⁹ Wang R-L, Yang Z-H, Huang Y-Y, et al. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke — CD131 knockdown abolishes protection; erythropoietic indices unchanged. CNS Neurosci Ther 2024;30:e14676. DOI 10.1111/cns.14676

¹⁰ Nairz M, Haschka D, Dichtl S, et al. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis — CD131-dependent, JAK2/PI3K/NF-κB; non-erythropoietic. Sci Rep 2017;7:13012. DOI 10.1038/s41598-017-13046-3

¹¹ van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, et al. ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury — porcine model, improved GFR, reduced interstitial fibrosis. J Transl Med 2013;11:9. DOI 10.1186/1479-5876-11-9

¹² Winicki NM, Nanavati AP, Morrell CH, et al. A small erythropoietin-derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age-associated declines in heart function and prolongs healthspan — aged-rat study, 100 µg/kg three times weekly; no lifespan change. Front Cardiovasc Med 2023;9:1096887. DOI 10.3389/fcvm.2022.1096887